While early DUR programs were innovative in their approach to improving medication utilization, their screening processes were not refined. The drawbacks to these programs included a limited number of screening criteria and the lack of a filtering mechanism for inconsequential and redundant information going to the pharmacy provider. For example, when the General Accounting Office evaluated automated OPDUR systems in the Medicaid populations of five states, they found that over a 12-month period pharmacists were alerted to more than 6.3 million prescriptions with the potential to cause adverse medical reactions3 Yet, only approximately 10% (650,000) of these prescriptions were actually cancelled because of potential serious risk to patients.
DEMONSTRATION PROJECT EVALUATES NEW OPDUR PROGRAMS
With the increased prevalence of OPDUR progràms, there would seem to be an increased need to understand the effects of these programs on practitioners. The ability of these programs to provide timely and useful information to providers has the potential to enhance patient care, while the inability to provide timely and useful information can bring an additionallevel of interference and inefficiency to the practice of pharmacy.
To address some of these issues, the HCFA, in collaboration with the Iowa Medicaid program, funded a demonstration project to assess a newer type of OPDUR system that was designed to filter redundant and inconsequential information.
Because of the refinements to the program, it was referred to as a "second-generation" DUR system. The details of this system have been published elsewhere.6 Briefly, customized software was designed which reviews (or filters) messages of clinical concern (screening failures) generated by typical firstgeneration systems and then determines which of those are most likely to be clinically important. 
General Results
Pharmacists also were asked general questions relating to the overall functioning of OPDUR (see Table 3 ). These questions dealt with how the system operates (ease of use), how the system affects patient care (impact on patients), and its value to pharmacists (effect on practice).
When specific system issues were addressed, pharmacists were quite positive in their assessments. Most Finally, the data did not suggest reasons for some pharma- 
